Trajan Scientific and Medical (Trajan) has enhanced its global leadership team with a number of key appointments:
Trajan’s leadership team also includes Anthony Audino, Vice President Global Business Development, Makoto Ohashi, Director Asia, Dr Andrew Gooley, Chief Scientific Officer, Alister Hodges, Chief Financial Officer, Mark Power, Global Quality and Continuous Improvement Manager, Hélène Lajoie, Global HR Manager, and Chris Clapham, Global Marketing Communications Manager.
Commenting on his growing team, Stephen Tomisich, Trajan’s Chief Executive Officer said, “We are building a strong, global commercial and technical team. We are proud that our core customers are some of the leading global enterprises in our industry. If we are to serve them at a standard beyond expectations then we must put in place the best team of people that we can gather; and that’s what we are doing.”
Trajan, formed in 2011, encompasses a group of companies including SGE Analytical Science, Grale HDS and SciMed Precision with over 300 staff worldwide. Trajan’s commitment to people development at all levels is essential to its success as a global operation.
“We believe that we are in a unique position to develop technologies that will deliver more sensitive,
selective and affordable analysis in biological, food and environmental applications.” said Mr Tomisich.
Trajan Scientific and Medical’s hemaPEN® microsampling technology has been developed with extensive consultation and evaluation by leading analytical laboratories, clinicians and healthcare professionals.
This month, Trajan presents an exclusive interview with researcher Dr Michele Protti of Pharmaco-Toxicological Analysis, Bologna, Italy, on the future of microsampling and the critical role hemaPEN can play when used in therapeutic drug monitoring for optimal therapy personalization.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.